Product Reports Resources Pricing Login Book a demo

InVitae

Biotech & Life Sciences · San Francisco, United States · Founded 2010 · IPO 2015

Bringing comprehensive, affordable, expert genetic insights into mainstream medical care. To read our community guidelines, visit https://t.co/mWqD4UMDer

Valuation $1.28B
Revenue $487M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

12 investors on InVitae's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Anya Schiess
Series B+ 11 investors entered at this stage
Genesys Capital
Thomas
Genomic Health
Casdin Capital
Perceptive Advisors
Decheng Capital
Rock Springs Capital
Wellington Management
Three Leaf Ventures
Redmile Group
OrbiMed

InVitae mafia

Startups founded by InVitae alumni

Former InVitae employees who went on to start their own companies. Sorted by Dealroom signal score.

e-LōvuEst. 2022
KGKamal GogineniUnited States
Signal score82
Nest GenomicsEst. 2022
GSGuy SnirUnited States
Signal score78
Xili TechnologyEst. 2021
YLYang LiUnited States
Signal score75
JustPaidEst. 2022
Vinay PinnakaUnited States
Signal score72
Enumera MolecularEst. 2022
KJKevin B JacobsUnited States
Signal score70
PipeEst. 2019
ZAZain AllarakhiaUnited States
Signal score68
MDisruptEst. 2019
Ruby GadelrabUnited States
Signal score66
Clarified Precision MedicineEst. 2022
Lisa AldersonUnited States
Signal score65
Molecular LoopEst. 2018
GPGreg PorrecaUnited States
Signal score65
Sano GeneticsEst. 2016
Patrick ShortUnited Kingdom
Signal score62
PerformicaEst. 2022
Alex FurmanUnited States
Signal score58

Book a demo to explore the full alumni network →

Global footprint

Where InVitae has talent and traffic

Workforce by country
14 countries with
team presence
🇺🇸 United States95.7%
🇦🇺 Australia0.6%
🇵🇭 Philippines0.6%
🇧🇷 Brazil0.4%
🇷🇸 Serbia0.2%
Top 5 of 14 shown
Web traffic by country
410K monthly visits
across markets
🇺🇸 United States91%
🇨🇦 Canada1.5%
🇦🇺 Australia1.1%
🇿🇦 South Africa0.7%
🇬🇧 United Kingdom0.5%
Top 5 markets shown

Talent graph

The shape of InVitae's talent

Dealroom maps InVitae's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

13 standout operatorsDealroom-flagged across the org
19 AI specialistsincl. 6 core researchers
678 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock InVitae's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$110M patent portfolio · 151 active families

Estimated portfolio value
$110M
8.6% of market cap · 21.7× smaller than top peer Illumina ($2.4B)
151 active patent families
Where InVitae innovates BioinformaticsMolecular biologyActive agentBiological organismBiology

Where InVitae concentrates vs peers

Each axis is a top-10 topic across InVitae and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

InVitae's 8 investments and acquisitions.

Every disclosed deal where InVitae appeared as a backer or acquirer, 2017–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

8 deals across InVitae's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where InVitae deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        InVitae's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        8 of 8 deals

        Market sentiment

        What the market is saying about InVitae

        An AI-synthesized read of the highest-engagement posts about InVitae on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See InVitae on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles